These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rifaximin and lubiprostone: the best options for treating irritable bowel syndrome? Purslow C Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):263. PubMed ID: 22816171 [No Abstract] [Full Text] [Related]
3. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. Schey R; Rao SS Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):461-4. PubMed ID: 21780893 [TBL] [Abstract][Full Text] [Related]
4. Rifaximin for the treatment of irritable bowel syndrome. Cremonini F; Lembo A Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066 [TBL] [Abstract][Full Text] [Related]
6. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541 [TBL] [Abstract][Full Text] [Related]
7. Antibiotic may improve irritable bowel syndrome. Mayo Clin Health Lett; 2007 Mar; 25(3):4. PubMed ID: 17396340 [No Abstract] [Full Text] [Related]
8. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. Kane JS; Ford AC Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693 [TBL] [Abstract][Full Text] [Related]
9. Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome. Vicari E; Salemi M; Sidoti G; Malaguarnera M; Castiglione R Nutrients; 2017 Nov; 9(11):. PubMed ID: 29099760 [TBL] [Abstract][Full Text] [Related]
10. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline. Rivkin A; Rybalov S Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716 [TBL] [Abstract][Full Text] [Related]
14. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. Peralta S; Cottone C; Doveri T; Almasio PL; Craxi A World J Gastroenterol; 2009 Jun; 15(21):2628-31. PubMed ID: 19496193 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. Bruzzese E; Pesce M; Sarnelli G; Guarino A Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844 [TBL] [Abstract][Full Text] [Related]
16. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Cash BD; Lacy BE; Rao T; Earnest DL Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529 [TBL] [Abstract][Full Text] [Related]
17. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Frissora CL; Cash BD Aliment Pharmacol Ther; 2007 Jun; 25(11):1271-81. PubMed ID: 17509095 [TBL] [Abstract][Full Text] [Related]
18. Clinical trials in irritable bowel syndrome: a review. Ervin CM; Mangel AW Rev Recent Clin Trials; 2013 Mar; 8(1):9-22. PubMed ID: 23130604 [TBL] [Abstract][Full Text] [Related]
19. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Meyrat P; Safroneeva E; Schoepfer AM Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1084-93. PubMed ID: 23066911 [TBL] [Abstract][Full Text] [Related]
20. [Variation of intestinal fermentative profile after sequential therapy with rifaximin/probiotics]. Dima G; Peralta D; Novillo A; Lasa J; Besasso H; Soifer L Acta Gastroenterol Latinoam; 2012 Jun; 42(2):99-104. PubMed ID: 22876711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]